Association Between Cabozantinib and Skin Reactions in Urothelial Carcinoma
the Cancer Therapy Advisor take:
The study was based in a single institution (the Clinical Research Center at the National Institutes of Health) and included 41 adult patients with metastatic, progressive urothelial carcinoma who were enrolled in a phase 2 clinical trial and receiving cabozantinib as monotherapy.
The patients were monitored for skin reactions after treatment between October 2012 and June 2014. The patients were evaluated by the primary oncology team and, when necessary, referred to a dermatologist. The researchers found that of the group of 41 evaluable patients, 73% (30 patients) developed at least one cutaneous toxic effect.
The adverse events included 22 patients with hand-foot reactions (54%), 18 pateints with generalized pigment dilution and/or hair depigmentation (44%), 8 patients with xerosis (20%), 6 patients with scrotal erythema/ulceration (15%), and 5 patients with nail splinter hemorrhages (12%).
Two or more cutaneous adverse events were seen in 18 patients (44%). Fifty-seven percent of patients (17 patients) had reactions within the first month of treatment, and 80% (24 patients) within the second month. The researchers concluded that cabozantinib monotherapy is associated with cutaneous adverse reactions in many patients and if the oncology team can detect reactions early and treat them effectively it may assist in a patients’ adherence to the treatment regimen.
The relationship and frequency skin reactions in urothelial carcinoma who are being treated only cabozantinib evaluated.
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|
|Renal Cell Carcinoma||Regimens||Drugs|
Cancer Therapy Advisor Articles
- Plastics and Cancer
- Real-World Study Shows High Response Rates to T-VEC in Early Metastatic Melanoma
- Cabozantinib Shows Promising Activity in Osteosarcoma and Ewing Sarcoma
- Using ctDNA to Predict Cancer Recurrence and Guide Therapy Selection
- Are Next-Gen Antibody-Drug Conjugates a Path Forward for Non-Hodgkin Lymphoma and Myeloma?
- First-Line Alectinib Effective in Asian Patients With ALK-Positive Advanced NSCLC
- Pembrolizumab Alone or With Chemotherapy Prolongs OS in Recurrent/Metastatic HNSCC
- Pembrolizumab With Dabrafenib and Trametinib Shows Efficacy, But High TRAEs, in Melanoma
- Assays May Help Researchers Discover Factors Underlying Immunotherapy Response
- Atezolizumab Combo Improved PFS, OS in Stage IV Non-Small Cell Lung Cancer